ATAHC: Australian trial in acute hepatitis C

This trial is concluded. This means the trial has been completed. The results of the trial are summarised in the 'results' section of this page. You cannot enrol in this trial.

About this trial

This study is following a large group of people with acute hepatitis C virusA small infective organism which is incapable of reproducing outside a host cell. (HCVHepatitis C virus.) to examine why some people naturally clear the virus and some don't. It will also monitor how many people become re-infected after clearing HCV and look into why this happened.

Three months into the study, everyone taking part has the option to undergo a six month course of pegylated interferon alfa 2a (plus ribavirinAn antiviral drug which is effective against a range of viruses including herpes, the hepatitis C virus and several strains of influenza. for those coinfected with HIV) as treatment for their hepatitis C. The purpose of this part of the study is to examine whether treatment is effective in clearing HCV.

Background information

The Trial is in the final stage of study analysis and study papers publication. The investigators anticipate that all trial activities will complete by June 2010.

Official title:

Australian Trial in Acute Hepatitis C

What is this trial studying?

existing_drug – ribavirin, interferon

Start date:

July 2004 (This may be the proposed or expected start date for trials which have not yet started.)

How many participants will this trial enrol?

167 (The exact number of participants may be lower or slightly higher than this. Some trials also have specific quotas for participants from each state, city or clinic.)

How long is this trial planned to go for?

Participants in this trial will be asked to take the trial drugs for 6 months. Following the conclusion of the trial, participants will be followed up for a further 60 months.

Links to further information:

• http://clinicaltrials.gov/ct2/show/NCT00192569?term=National+Centre+in+HIV+Epidemiology+and+Clinical+Research+AND+HIV&cntry1=PA%3AAU&rank=6

Can I access this treatment other than by enrolling in this trial?

Pegylated interferon alpha 2a and ribavirin are PBS approved drugs.

Who can enrol in this trial?

You may be eligible to participate in this trial if you meet the following criteria:

• At least 16 years old
• HIV-positive
• Positive antibody test for hepatitis C virus (HCV)

This is a summary of key inclusion and exclusion criteria for this trial. There may be other criteria which may exclude some people from participation in this trial. Some laboratory tests may also be required. Consult your doctor, or view the trial protocol or informed consent documentation to see the full range of exclusion and inclusion criteria.

Results:

For a review of outcomes of this trial see attachment: Dore_Gastroenterology_2010

Disclaimer

While NAPWA has taken every care to compile the information on this page and to keep it up-to-date, we cannot guarantee its correctness and completeness.

Before making the decision to participate in any clinical research, visit the NAPWA website for background information on participating in clinical research.

Contact NAPWA if you have any questions or comments about this trial.